Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 17 · below the Ichimoku cloud · RSI 24 (oversold) · MACD above its signal · 8% above its 52-week low
None of the 29 investors followed here reported a position in BBLG in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BBLG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BBLG.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.1 | -29.8 | -4.5 | 17.3 | 2.3 | 3.8 | -38.2 | -31.8 | -14.0 | -13.3 | −70.3% | ||
| 2025 | 18.1 | -19.9 | -10.0 | -15.9 | 30.8 | -23.7 | -30.5 | -23.2 | 29.8 | -23.7 | -29.6 | -3.3 | −74.3% |
| 2024 | -19.7 | -32.5 | -13.1 | -26.7 | 6.3 | -26.5 | 77.0 | -35.2 | 52.1 | -36.6 | -9.6 | -23.0 | −79.2% |
| 2023 | 34.8 | 4.2 | -12.2 | 0.4 | -34.6 | -72.0 | -10.5 | -47.1 | 4.9 | -26.1 | -22.1 | 38.1 | −91.0% |
| 2022 | -39.2 | -15.0 | 52.7 | -21.6 | -27.3 | -11.7 | -8.6 | 4.7 | -21.6 | -57.1 | -33.3 | -30.0 | −94.0% |
| 2021 | -27.4 | -3.0 | −29.6% |
Buy / hold / sell counts
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.